We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Speculating in Takeover Targets
ULBI 11.92+1.2%Jul 23 3:59 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
Recommended by:
To: E_K_S who wrote (5725)12/19/2019 12:06:29 PM
From: E_K_S1 Recommendation  Read Replies (1) of 7075
ACST +9% new recovery high last $2.60/share. Not really a merger/buy out (maybe in the future) but Phase III results for their krill oil based drug (similar to Vascepa discovered/approved for AMRN) s/d be out this week.

Company said end of year and getting close to end of the year. Have shares at $0.86/share and more last week at $1.85/share. Could be a very Merry Christmas at the EKS household.

Good investing

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext